Choosing a contract API manufacturer is one of the highest-stakes decisions a procurement or CMC team makes.
Get it right, and your clinical and commercial supply runs smoothly. Get it wrong, and you face manufacturing delays, regulatory observations, or IP exposure that can derail your entire program.
Most supplier evaluations are too thin. A GMP certificate and a site visit are not enough. Here are ten questions every procurement lead should ask before committing.
1. What regulatory authorities have inspected this facility, and what were the outcomes?
The manufacturer should have been inspected by at least one major authority (USFDA, EMA, WHO, PMDA) in the past three years. Check the FDA’s warning letter database and EudraGMDP for EU records. Unresolved critical observations are a risk you should not accept.
LAXAI: GMP manufacturing site in Hyderabad operates under established quality systems supporting US and EU-regulated CMC programs.
2. What GMP certifications does the facility hold, and are they current?
Certifications must be current and issued by recognized authorities. CGMP compliance manufacturer must demonstrate the facilities, equipment, and processes to produce the drug they intend to market. Ask for the explicit scope of certification, not just the certificate itself.
LAXAI: GMP certifications cover small molecule APIs, advanced intermediates, key starting materials, and regulatory starting materials.
3. What is the manufacturer’s experience with your specific chemistry type?
Relevant chemistry experience reduces execution risk significantly. Ask for examples, not general claims. How many similar programs have they completed? What reaction types and scale ranges have they handled?
LAXAI: Over 150 completed CMC projects with specific expertise in high-energy chemistries, high-pressure reactions, and complex small molecule synthesis.
4. What is the manufacturer’s capacity, and can it scale with your program?
A manufacturer that handles a Phase I tox batch but cannot scale to Phase III supply forces a disruptive technology transfer mid-program. Ask about reactor size range, batch size flexibility, and current utilization rates.
LAXAI: Manufactures from preclinical and first-in-human (FIH) supply through late-phase and commercial quantities, with tech transfer and process validation in-house.
5. How does the manufacturer handle IP security Pharma?
A contract API manufacturer should have documented procedures for information segregation and access controls. Ask specifically whether they manufacture for competitors in the same therapeutic area.
LAXAI: Operates under strict confidentiality agreements with program-level information segregation as standard practice.
6. What analytical capabilities does the manufacturer have in-house?
If every analytical question requires a third-party lab, timelines stretch and data integrity risks multiply. Look for HPLC, GC, LC-MS, NMR, and ICH-compliant method validation under one roof.
LAXAI: In-house analytical team covers method development, validation and transfer, impurity profiling, forced degradation studies, and reference standard qualification.
7. What is the approach to impurity control and genotoxic impurity management?
Regulatory agencies require full impurity characterization for APIs entering clinical development. A competent manufacturer identifies potential impurities during process development, not after a batch fails. Ask specifically about their GTI assessment process.
LAXAI: Impurity profiling and forced degradation studies are integrated into the development workflow. Analytical and process chemistry teams work in parallel from route selection onward.
8. What does the quality management system look like?
A robust QMS includes documented deviation procedures, CAPA processes, change control, and batch record integrity. Per FDA ICH Q7 guidance, regular internal audits and product quality reviews are mandatory. Ask to see their audit schedule.
LAXAI: QA and regulatory support team maintains documentation-ready quality systems aligned with FDA and ICH Q7 expectations.
9. Can the manufacturer support regulatory filings and tech transfer?
Your contract API manufacturer should generate CMC documentation that supports IND, IMPD, NDA, or ANDA filings. Ask whether they have regulatory affairs staff on site and whether they have supported FDA or EMA submissions before.
LAXAI: Dedicated regulatory team supports filing, process validation, and tech transfer. Programs are designed from the start with submission documentation in mind.
10. What does the project management and communication model look like?
Ask about project management structure, reporting cadence, and escalation procedures. A manufacturer that proactively flags risks is worth more than one that only communicates when something goes wrong.
LAXAI: Client organizations consistently describe the LAXAI team as their extended R&D arm, reflecting deep integration rather than a transactional vendor relationship.
The Bottom Line on Your Evaluation Procurement Checklist
A thorough API manufacturer audit covers regulatory compliance, technical capability, IP security, analytical depth, and relationship quality. LAXAI covers all ten categories with a documented track record.
Contact LAXAI at bd@laxai.com to begin the qualification conversation.
FAQs
What should I check first when evaluating a contract API manufacturer? Start with regulatory inspection history, pharma. Check the FDA warning letter database and EudraGMDP. A clean inspection record from a recognized authority is the baseline requirement.
Does FDA require me to audit my API supplier? Yes. FDA CGMP regulations and ICH Q7 place responsibility on the drug product manufacturer for their API supplier qualification through audits, documentation review, and ongoing performance monitoring.What is the difference between a CMO and a CDMO for API manufacturing? A CMO focuses on production. A CDMO adds process development, analytical development, and regulatory support. For early-phase programs, a CDMO like LAXAI reduces handoffs and maintains scientific continuity from development through supply.
